Board of Directors
Dr.
Robert Wilkins
Endovalve President and CEO
Tracy Warren
General Partner, Battelle Ventures and Innovation Valley Partners
Ms. Warren focuses primarily on investments
in healthcare, life sciences and emerging energy technologies, and
led the firms’ healthcare investments in Endovalve and NuPathe,
a CNS specialty pharmaceutical company. In the healthcare sector,
she serves on the Board of Directors of Endovalve and is a Board
observer for NuPathe.
In sectors other than healthcare, Ms. Warren
also led investments in Metatomix
(Board member),
SmartSynch (Board observer) and Superprotonic (Board observer).
Prior to joining a venture capital
firm in 2000, when she became an associate at Battelle Ventures’ predecessor
fund, Ms. Warren spent three years at SG Cowen Securities, first
as an analyst
in Healthcare Mergers and Acquisitions, then as an associate
in Corporate Finance. While at SG Cowen, she focused on companies
in the medical device and healthcare information technology
fields.
Ms. Warren began her career in the Global Financial
Analyst program at Chase Manhattan Bank. She holds a B.S. degree
in accounting
and international business from New York University Stern
School of Business, and an M.B.A in finance and entrepreneurial studies
from Columbia Business School.
Kurt Dasse, Ph.D.
President and CEO, Levitronix, LLC
Dr. Dasse has spent nearly three decades conducting
research in cardiovascular disorders and developing medical devices,
including products for percutaneous and vascular access. He currently
heads Waltham, Mass.-based technology company Levitronix, LLC, a
developer and maker of a new generation of blood pumps and ultra-pure
fluid handling components for the semiconductor industry. Dr. Dasse
joined Levitronix in 2000 as president of its Medical Division. He
also serves as Chief Operating Officer of Levitronix’s parent
company, Pharos LLC.
Previously, Dr. Dasse was Chief Scientist and
vice president of $700-million Thermo Electron Corporation’s
Biomedical Group, where the
company focused on developing products for the
respiratory, neurodiagnostic, cardiovascular and imaging markets.
He also was a founding officer of Thermo Cardiosystems and played
a key role in commercializing the first implantable ventricular assist
system for end-stage heart-failure patients.
A former Core Technology Advisory Board member
for Battelle Memorial Institute, and Scientific Advisory Board member
for Cardeon, he previously served as a director of Given Imaging,
and is currently a director of Afferent Corporation.
Dr. Dasse received a B.A. degree in biology from
the University of Massachusetts, and his doctorate in medical physiology
from Boston University School of Medicine. He has written more than
75 journal articles and multiple book chapters, and holds five patents.
Investors
Battelle Ventures (www.battelleventures.com) and its affiliate
fund, Innovation Valley Partners (www.innovationvalleypartners.com),
are the only current investors in Endovalve.
> Back to Top
|
